PositiveID expected to announce key acquisition Print E-mail
By Peter Depalma   
Wednesday, 17 February 2010 07:59
PositiveID Corporation (NASDAQ: PSID) is expected to announce today that it has acquired intellectual property rights and assets of a company that will expand its portfolio of non-invasive glucose-level testing products.


According to several sources, the company- which our subscribers were alerted about late last week, will acquire a technology that allows for non-invasive glucose detection measured through a patient’s exhaled breath.

As reported here, PositiveID has partnered with RECEPTORS LLC in the development of a glucose sensor on the end of an implantable RFID microchip. Presently, diabetic patients must prick themselves 2-3 times daily to test and monitor glucose levels. For years, the diabetic community has been longing for a non-invasive method of glucose monitoring. PositiveID’s methodology and technology could end up being the diabetes patient community’s Holy Grail.

Patients would receive a subcutaneous injection in their arm whereby a small RFID microchip, the size of a grain of rice would be implanted. By using an ASIC (under development) as a communication device, one would simply wave a scanner over the arm and blood sugar readings would be displayed. Management is forecasting that a new chip would have to be implanted every 6-12 months. However, that is not likely to be viewed as a negative.
“I believe that 99% would say give me a shot every 6-12 months rather than prick their finger 3 times a day,” noted Silverman.


Disclosure: No Positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus